Orforglipron

Key Benefits#

• Oral pill — no injections required
• Once-daily dosing without food restrictions (unlike oral semaglutide)
• Up to 9.4% body weight reduction in Phase 2 at 36 weeks
• Significant HbA1c reduction in type 2 diabetes trials
• Small-molecule stability — no cold chain requirements
• Broadens access for injection-averse patients
• Potential class-defining convenience advantage over injectable GLP-1s

Mechanism of Action#

Orforglipron is a small-molecule allosteric agonist of the GLP-1 receptor. Unlike peptide-based GLP-1 agonists, it does not require injection and is stable in the gastrointestinal tract. It activates the same downstream pathways as semaglutide — suppressing appetite via hypothalamic GLP-1 receptors, stimulating glucose-dependent insulin release, and slowing gastric emptying — but with the convenience of an oral pill taken once daily without food restrictions.

Dosing Protocols#

Side Effects#

• Nausea (most common, dose-dependent)
• Vomiting
• Diarrhea
• Decreased appetite
• Constipation
• Dyspepsia

Contraindications#

Not FDA approved — Phase 3 trials ongoing. Caution with history of pancreatitis. Renal/hepatic impairment considerations.

Storage#

Room temperature storage expected (small molecule, not a peptide). Per manufacturer guidelines.

1. 1.
   Oral GLP-1 receptor agonists for the treatment of obesity: ATTAINing metabolic benefits to find the OASIS

   Vafeidou K, Koufakis T, Stavropoulos K, Zarfeiadou M, Doumas M, Patoulias D · Expert review of endocrinology & metabolism · 2026PubMed Verified

2. 2.
   Comparative Efficacy and Safety of Different Orforglipron Doses in Patients With Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Network Meta-Analysis

   Tantoush M, Almaghrabi Y, Abusbaeh A, Ahmed N, Tantush A, Ben Hamida B et al. · Cureus · 2026ReviewPubMed Verified

3. 3.
   Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review

   Alper A, Peleg G, Fagin A, Shah P, Chowdhury I, Gonzales A et al. · Cardiovascular diabetology. Endocrinology reports · 2026ReviewPubMed Verified

4. 4.
   Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes

   Kansakar U, Jankauskas SS, Pande S, Mone P, Varzideh F, Santulli G · International journal of molecular sciences · 2026ReviewPubMed Verified

5. 5.
   Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis

   Hammad N, Ramadan AM, Nazmy A, Elazab A, Abdelaziz A · Diabetes technology & therapeutics · 2026PubMed Verified

6. 6.
   Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials

   Zhang Y, Zhang C, Gong X, Cheng P, Fu H, Diao L et al. · European journal of medical research · 2026Meta-AnalysisPubMed Verified

7. 7.
   Modelling G protein-biased agonism using GLP-1 receptor C-terminal mutations

   Tran HD, Zuo Y, Wong C, Pollard A, Bloom S, Jones B · Molecular metabolism · 2026PubMed Verified

8. 8.
   Generation and characterisation of a humanised GLP-1 receptor mouse model for translational drug development

   Sonne N, Roque M, Zachariassen LF, Porsgaard T, Pors SE, Cavalera M et al. · EBioMedicine · 2026PubMed Verified

9. 9.
   Efficacy and safety of orforglipron in type 2 diabetes mellitus and obesity: a GRADE-assessed meta-analysis and trial sequential analysis with subgroup evaluations by diabetic status, obesity status, and dose regimens

   Jamal A, Khan S, Qadri M, Shah A, Iftikhar H, Fatima E et al. · Acta diabetologica · 2026ReviewPubMed Verified

10. 10.
    Rewriting Diabetes Therapy: How Incretin Modulation is Transforming Cardiovascular and Renal Outcomes

    Miramontes-González JP, Rodrigo-Alaíz Á, Gabella-Martín M, González-Calle D, Carretero-Gómez J, Corral-Gudino L · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026ReviewPubMed Verified

11. 11.
    Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis

    Bhattarai HB, Paudel BS, Parajuli SR, Dahal K, Shah S, Bhattarai M et al. · Medicine · 2025Meta-AnalysisPubMed Verified

12. 12.
    The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis

    Zhou J, Wang F, Li S · Frontiers in endocrinology · 2025Meta-AnalysisPubMed Verified

13. 13.
    Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes

    Pillai AA, Sharma AM, Krayem H, Frishman WH, Aronow WS · Cardiology in review · 2025PubMed Verified

14. 14.
    Medical Management of Obesity: A Comprehensive Review of Food and Drug Administration (FDA)-Approved and Investigational Therapies

    Raza SS, Zakir Z, Hashmat A, Awan SK, Varrassi G · Cureus · 2025ReviewPubMed Verified

15. 15.
    The Obesity Drug Revolution: New Frontiers in Pharmacotherapy

    Manoria PC · Cureus · 2025ReviewPubMed Verified

16. 16.
    One small molecule for man, one giant leap for mankind with obesity

    Novikoff A, Müller TD · Med (New York, N.Y.) · 2025PubMed Verified

17. 17.
    Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes. Reply

    Rosenstock J, Cox D, Denning M · The New England journal of medicine · 2025PubMed Verified

18. 18.
    Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes

    Xie X, Xuan X · The New England journal of medicine · 2025PubMed Verified

19. 19.
    Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes

    Jagarlapudi SP · The New England journal of medicine · 2025PubMed Verified

20. 20.
    Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes

    Nagaoka T · The New England journal of medicine · 2025PubMed Verified

21. 21.
    Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon

    Abdelrahman RM, Musa TH, Arbab IA, Suliman MH, Ahmed EO, Mohamed AN et al. · Journal of obesity · 2025ReviewPubMed Verified

22. 22.
    A phase 1 single and multiple ascending dose study of orforglipron in Japanese participants with type 2 diabetes

    Ohwaki K, Nakamura C, Nasu R, Takenouchi K, Hirase T · Journal of diabetes investigation · 2026RCTPubMed Verified

23. 23.
    Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review

    Takrori E, Peshin S, Singal S · Medicina (Kaunas, Lithuania) · 2025Meta-AnalysisPubMed Verified

24. 24.
    Engineered nutrient-stimulated hormonal multi-agonist for precision targeting of obesity and metabolic disorders

    Cho YK, Jung CH · Clinical and molecular hepatology · 2025PubMed Verified

25. 25.
    Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta-Analysis

    Pandey RK, Jan M, Mohammad A, Jawaid KA, Naveed M, Abid MA et al. · Endocrinology, diabetes & metabolism · 2025Meta-AnalysisPubMed Verified

26. 26.
    Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial

    Horn DB, Ryan DH, Kis SG, Alves B, Mu Y, Kim SG et al. · Lancet (London, England) · 2026RCTPubMed Verified

27. 27.
    Orforglipron in type 2 diabetes mellitus and obesity: an overview

    Panou T, Gouveri E, Popovic DS, Papanas N · Expert review of clinical pharmacology · 2025ReviewPubMed Verified

28. 28.
    Novel GLP-1-Based Medications for Type 2 Diabetes and Obesity

    Son JW, le Roux CW, Blüher M, Nauck MA, Lim S · Endocrine reviews · 2025PubMed Verified

29. 29.
    From needles to pills: oral GLP-1 therapy enters the obesity arena

    Santulli G · Cardiovascular diabetology. Endocrinology reports · 2025PubMed Verified

30. 30.
    In early T2D inadequately controlled with diet and exercise, once-daily orforglipron reduced HbA(1c) vs. placebo at 40 wk

    Shahid M, Gandhi GY, ACP Journal Club Editorial Team at McMaster University · Annals of internal medicine · 2025RCTPubMed Verified

31. 31.
    Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment

    Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K et al. · The New England journal of medicine · 2025RCTPubMed Verified

32. 32.
    Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare

    Bhat S, Fernandez CJ, Lakshmi V, Pappachan JM · World journal of cardiology · 2025ReviewPubMed Verified

33. 33.
    Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants

    Morse BL, Bhattachar S, Ma X, Coutant DE, Czeskis B, Nicoll C et al. · Clinical pharmacology in drug development · 2026Clinical TrialPubMed Verified

34. 34.
    Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis

    Nong K, Jeppesen BT, Shi Q, Agoritsas T, Guyatt GH, White H et al. · BMJ (Clinical research ed.) · 2025Meta-AnalysisPubMed Verified

35. 35.
    Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes

    Rosenstock J, Robins DA, Duffin KL, Wilson JM, Lin Y, Banerjee H et al. · Diabetes, obesity & metabolism · 2025RCTPubMed Verified

36. 36.
    Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis

    Ismaiel A, Scarlata GGM, Boitos I, Leucuta DC, Popa SL, Al Srouji N et al. · International journal of obesity (2005) · 2025Meta-AnalysisPubMed Verified

37. 37.
    Incretin-based therapies for the treatment of obesity-related diseases

    Caruso I, Cignarelli A, Sorice GP, Perrini S, Giorgino F · npj metabolic health and disease · 2024ReviewPubMed Verified

38. 38.
    Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes

    Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu WS et al. · The New England journal of medicine · 2025RCTPubMed Verified

39. 39.
    Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes

    Wharton S, Rosenstock J, Konige M, Lin Y, Duffin K, Wilson J et al. · Cardiovascular diabetology · 2025RCTPubMed Verified

40. 40.
    Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review

    Luna Ceron E, Reddy SD, Kattamuri L, Muvva DM, Chozet L, Bright T · Journal of Brown hospital medicine · 2025Meta-AnalysisPubMed Verified

41. 41.
    Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials

    Guo H, Yang J, Huang J, Xu L, Lv Y, Wang Y et al. · Obesity pillars · 2025PubMed Verified

42. 42.
    Emerging pharmacotherapies for obesity: A systematic review

    Kokkorakis M, Chakhtoura M, Rhayem C, Al Rifai J, Ghezzawi M, Valenzuela-Vallejo L et al. · Pharmacological reviews · 2025Meta-AnalysisPubMed Verified

43. 43.
    Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis

    Zhang S, Yu B, Xu J, Jin S, Li Y, Bing H et al. · Diabetes technology & therapeutics · 2025Meta-AnalysisPubMed Verified

44. 44.
    Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis

    An X, Sun W, Wen Z, Duan L, Zhang Y, Kang X et al. · Diabetes, obesity & metabolism · 2025Meta-AnalysisPubMed Verified

45. 45.
    The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron

    Sloop KW, Cox AL, Wainscott DB, White A, Droz BA, Stutsman C et al. · Science translational medicine · 2024PubMed Verified

46. 46.
    Oral GLP-1 Receptor Agonists for Weight Loss

    Krinsky D, Marcucci A, Mullally JA, Frishman WH · Cardiology in review · 2024PubMed Verified

47. 47.
    Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article

    Sidrak WR, Kalra S, Kalhan A · Indian journal of endocrinology and metabolism · 2024ReviewPubMed Verified

48. 48.
    Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials

    Lütkemeyer C, Pasqualotto E, Ferreira ROM, Chavez MP, Petris I Jr, Dos Santos HV et al. · Archives of endocrinology and metabolism · 2024Meta-AnalysisPubMed Verified

49. 49.
    Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials

    Xie Z, Zheng G, Liang Z, Li M, Deng W, Cao W · Metabolism: clinical and experimental · 2024Meta-AnalysisPubMed Verified

50. 50.
    Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?

    Gogineni P, Melson E, Papamargaritis D, Davies M · Expert opinion on pharmacotherapy · 2024ReviewPubMed Verified